Apellis Pharmaceuticals Inc EBITDA margin
Quel est le EBITDA margin de Apellis Pharmaceuticals Inc?
Le EBITDA margin de Apellis Pharmaceuticals Inc est -44,492.23%
Quelle est la définition de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin des entreprises dans Health Care secteur sur NASDAQ par rapport à Apellis Pharmaceuticals Inc
Que fait Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Entreprises avec ebitda margin similaire à Apellis Pharmaceuticals Inc
- Walkabout Resources a EBITDA margin de -47,688.31%
- Blue Star Helium a EBITDA margin de -47,121.89%
- Mont Royal Resources a EBITDA margin de -45,543.49%
- Checkpoint Therapeutics Inc a EBITDA margin de -45,501.28%
- Metallica Minerals a EBITDA margin de -45,139.43%
- Zeus Resources a EBITDA margin de -44,666.24%
- Apellis Pharmaceuticals Inc a EBITDA margin de -44,492.23%
- Nuveen NASDAQ 100 Dynamic Overwrite Fund a EBITDA margin de -44,294.34%
- Leonovus a EBITDA margin de -44,280.00%
- Lakes Oil NL a EBITDA margin de -43,029.19%
- Aimmune Therapeutics Inc a EBITDA margin de -42,733.57%
- Woomera Mining a EBITDA margin de -42,253.84%
- Amarillo Biosciences a EBITDA margin de -40,922.42%